3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
11
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
2
Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent/ Advanced Stage Endometrial Cancer Patients
1
Platinum-resistant Ovarian Cancer
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Nausea
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Kenny-Caffey syndrome, Type 1
1
Gonadal Disorders
1
Glioblastoma
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Endometrial Neoplasms
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Interventions
Cyclophosphamide
3
isatuximab
2
Lenalidomide
2
Dexamethasone
2
pomalidomide
1
penpulimab
1
olaparib
1
niraparib
1
fludarabine
1
anlotinib
1
Sorafenib
1
Rituximab
1
Ranitidine
1
Oxaliplatin
1
Gemcitabine
1
Diphenhydramine
1
Chemoradiotherapy
1
Bortezomib
1
Bevacizumab
1
Bendamustine Hydrochloride
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms by Histologic Type
×
niraparib
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled